Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
GIORGIO TRINCHIERI · DIVISION OF BASIC SCIENCES - NCI · 2022 · $741,872 — Progress has been made in several of the aims of the project. Tristetraprolin expression by keratinocytes protects against skin carcinogenesis: Cancer is caused primarily by genomic alterations resulting in deregulation of gene regulatory circuits in key growth, apoptosis, or DNA repa…
Bernard Moss · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $575,536 — Poxviruses encode enzymes and factors needed for transcription and replication of their genomes within the cytoplasm of infected cells. Vaccinia virus, the prototypic member of the poxvirus family, provides a unique system for combining biochemical and genetic approaches for investigating mechanisms…
Susan Moir · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $82,612 — In 2022, we conducted and contributed to several clinical research studies on COVID-19. We evaluated antibody and B-cell responses following infection and/or vaccination and contributed to the analysis of innate responses in patients hospitalized with COVID-19. Our efforts focused on three types of …
Lesia Dropulic · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $3,109,113 — Evaluation of the investigational vaccines in this project are part of the VRC mission related to biodefense and emerging pathogens. Targets include influenza, Ebola, malaria, and others. Further evaluation of vaccine approaches will continue as the VRC develops additional candidate vaccine regimens…
adrian u wiestner · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2022 · $1,663,921 — Monoclonal antibodies (mAbs) combined with chemotherapy improve survival of lymphoma patients. Fc receptor-dependent effector mechanisms achieve tumor cell killing but also induce antigen loss through trogocytosis. Activation of complement can lead to cell lysis and invariably deposits complement C3…
George N. Pavlakis · DIVISION OF BASIC SCIENCES - NCI · 2022 · $1,137,140 — We explored the biology of IL-15 and showed that efficient production of IL-15 is possible only by co-expression in the same cell with the so-called IL-15 Receptor-alpha. We have shown that IL-15 injection accelerates the recovery of lymphocytes in mice rendered lymphopenic after trea…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2022 · $1,155,919 — The elicitation of cross-neutralizing or broadly neutralizing Abs (bNAbs) to diverse HIV strains by Env vaccination remains a high priority for a broadly efficacious vaccine. The elicitation of bNAbs against conserved Env determinants remains elusive; however, the recent isolation of bNAbs to the fu…
BALI PULENDRAN · STANFORD UNIVERSITY · 2022 · $309,746 — ABSTRACT – Project 1 In the current proposal, we will use systems biological approaches to address two fundamental issues in vaccinology. The first issue concerns the immunology of COVID-19 vaccines, which utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine). The second…
Karen S. Anderson · YALE UNIVERSITY · 2022 · $435,036 — SUMMARY Human papillomavirus (HPV)-associated neck squamous cell carcinoma (HNSCC) represents an increasing proportion of HNSCC. The incidence of HPV+ HNSCC has dramatically increased over the last 2 decades and in 2012 surpassed uterine cervical cancer as the most common HPV-related malignancy in t…
Genevieve Giny Fouda Amou ou · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $343,969 — ABSTRACT – Project 2 Globally, about 600,000 young adults (15-24 years of age) became infected with HIV-1 in 2017. Young women age 15-19 years are most affected, and HIV-infection in this age group continue to rise. Therefore, a vaccine to prevent HIV acquisition in young adults remains a top priori…
Steven M Lipkin · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $117,052 — Admin Core: Project Summary/Abstract A significant overall goal of CAP-IT is to identify and validate immunologically targeted agents for precision prevention of individuals with increased cancer risk. The CAP-IT Center for RNA Immunoprevention (CRI) Administrative Core (AC) mission is to ensure tha…
MARGIE CLAPPER · RESEARCH INST OF FOX CHASE CAN CTR · 2022 · $614,163 — Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In the Unites States, an estimated 151,300 Americans will be diagnosed with CRC and over 52,580 are expected to die from the disease in 2022 alone (https://seer.cancer.gov/statfacts/html/colorect.html). While…
PYONE AYE · TULANE UNIVERSITY OF LOUISIANA · 2022 · $262,752 — The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prev…
Kari C. Nadeau · STANFORD UNIVERSITY · 2023 · $275,956 — 1 ABSTRACT – Clinical Core 2 The Clinical Core of the Stanford HIPC U19 will provide state-of-the-art clinical and biospecimen support for all 3 the research projects, the Immune Monitoring and the Data Management and Analysis Cores, as well as the 4 expertise, facilities, personnel, procedures a…
Bernard Moss · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $1,717,946 — During F7'23 progress has been made in developing an improved vaccine for mpox and infections caused by other orthopoxviruses. One approach carried in collaboration with the company Moderna uses mRNAs expressing four modified mpox virus proteins encapsulated in a lipid particle. We have shown that …
Lesia Dropulic · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $1,923,376 — The purpose of this Vaccine Research Center (VRC) Clinical Trials Program (CTP) project is to screen volunteers for protocols that involve the administration of investigational agents and to collect human specimens, such as blood, mucosal secretions, skin swabs, skin biopsy, or other body fluids, an…
DEBORAH M HINTON · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2023 · $459,883 — Nearly all virulence factors in Bordetella pertussis are activated by a master two-component system, BvgAS, composed of the sensor kinase BvgS and the response regulator BvgA. When BvgS is active, BvgA is phosphorylated (BvgAP), and virulence activated genes are expressed (the Bvg(+) mode). When B…
Pamela Frischmeyer-Guerrerio · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $754,258 — In FY23, we completed all study visits for our phase 2 randomized, double-blinded, placebo-controlled trial (COvid-19 Vaccine Associated Allergic Reactions trial; COVAAR) where 16 participants who previously reported a systemic allergic reaction (SAR) to their first dose of a COVID-19 mRNA vaccine w…
Christina Annunziata · DIVISION OF BASIC SCIENCES - NCI · 2023 · $587,759 — Goal 1: Monocytes It has been shown in mouse models of chemically induced cancer that Interferons (IFNs) are important in the immune-surveillance and immune-editing of tumors. While IFNs alpha (IFNa) and gamma (IFNg) have been shown to have potent anti-neoplastic and anti-proliferative properties in…
NANCY J SULLIVAN · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $18,581 — In these studies, we are evaluating a vaccine against Monkeypox that utilizes an mRNA platform, which has a more favorable safety profile and scalability. Manufacturing is also scalable with a short lag time from immunogen design to production making it amenable for rapid deployment of new antigens …